Successful transition to encorafenib following vemurafenib-induced drug rash with eosinophilia and systemic symptoms syndrome

Peter A Young; Lia C Keller; Gordon H Bae

doi:10.1016/j.jdcr.2020.12.030

Successful transition to encorafenib following vemurafenib-induced drug rash with eosinophilia and systemic symptoms syndrome

JAAD Case Rep. 2021 Jan 11:9:42-44. doi: 10.1016/j.jdcr.2020.12.030. eCollection 2021 Mar.

Authors

Peter A Young¹, Lia C Keller¹, Gordon H Bae²

Affiliations

¹ Department of Dermatology, The Permanente Medical Group, Sacramento, California.
² Department of Dermatology, Stanford University School of Medicine, Red Wood City, California.

No abstract available

Keywords: BRAF inhibitors; DRESS, drug reaction with eosinophilia and systemic symptoms; MEK inhibitors; RESS syndrome; SCARs; checkpoint inhibitors; cobimetinib; dabrafenib; drug reaction with eosinophilia and systemic symptoms; encorafenib; malignant melanoma; metastatic melanoma; pembrolizumab; severe cutaneous adverse reactions; vemurafenib.

Publication types

Case Reports